The US Food and Drug Administration (FDA) approved prescription nalmefene hydrochloride nasal spray, an opioid receptor antagonist. Nalmefene, sold as Opvee, can be used to treat adults and children aged 12 years or older who are experiencing a known or suspected opioid overdose, according to the FDA’s statement.
Source: JAMA Online First